STOP-NSCLC, HALT, and NCT03808662 trials examined the efficacy and safety of SBRT of all progressions in patients with OPD after response to systemic chemotherapy, and the results of these trials may allow us to evaluate the efficacy and safety of a strategy of continuation of treatment beyond PD with the addition of LAT in OPD, with and without driver mutations. The gene discussed is LAT; the disease is non-small cell lung carcinoma.